London, United Kingdom

Martin Pulé

This inventor holds 72 USPTO granted patents and 94 published patent applications, plus 2 CIPO patents and 37 EPO patents, primarily in Chimeric Antigen Receptors (CPC class C07K). Top assignees: Autolus Limited, Ucl Business Plc. Active years: 2018-2026.

USPTO Granted Patents = 72 

% Patents Active = 91.7

 

 

Average Co-Inventor Count = 3.3

ph-index = 5

Forward Citations = 127(Granted Patents)

Forward Citations (Not Self Cited) = 65(Dec 10, 2025)


Inventors with similar research interests:


Company Filing History:


Years Active: 2018-2026

Loading Chart...
Loading Chart...
Loading Chart...
Areas of Expertise:
Chimeric Antigen Receptor
T-Cell Modulation
Cancer Treatment
Transgenic T-Cell Receptor
Bi-Specific T-Cell Engager
Cytokine Receptor
Nucleic Acid Construct
Retroviral Vectors
Lentiviral Vectors
T-Cell Receptor
CAR T-Cells
Transcriptional Circuits
72 patents (USPTO):Explore Patents

Title: Martin Pulé - Innovative Inventor from London, GB

Introduction: Martin Pulé is a renowned inventor based in London, United Kingdom, known for his groundbreaking contributions to various industries.

Latest Patents: Martin Pulé holds several patents in the fields of technology, healthcare, and sustainable energy, showcasing his diverse range of expertise and innovation.

Career Highlights: With a career spanning over two decades, Martin Pulé has worked with leading research institutions and companies to develop cutting-edge solutions that have revolutionized the way we live and work.

Collaborations: Throughout his career, Martin Pulé has collaborated with top universities, multinational companies, and forward-thinking startups to bring his inventions to life and make a positive impact on society.

Conclusion: Martin Pulé's passion for innovation and his relentless pursuit of excellence continue to drive him to create solutions that shape the future and inspire the next generation of inventors.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to [email protected]
Loading…